{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:57:54Z","timestamp":1761397074544,"version":"3.41.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07018-1","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:01:44Z","timestamp":1751446904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of aflibercept combined with 80% dose photodynamic therapy for pachychoroid neovasculopathy"],"prefix":"10.1038","volume":"15","author":[{"given":"Norihiko","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issei","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"7018_CR1","doi-asserted-by":"crossref","unstructured":"Pang, C. E. & Freund, K. B. Pachychoroid neovasculopathy. Retina 35, 1\u20139 (2015).","DOI":"10.1097\/IAE.0000000000000331"},{"key":"7018_CR2","doi-asserted-by":"publisher","first-page":"16204","DOI":"10.1038\/srep16204","volume":"5","author":"M Miyake","year":"2015","unstructured":"Miyake, M. et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci. Rep. 5, 16204 (2015).","journal-title":"Sci. Rep."},{"key":"7018_CR3","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s41598-019-38504-y","volume":"9","author":"BJ Jung","year":"2019","unstructured":"Jung, B. J. et al. Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy. Sci. Rep. 9, 2055 (2019).","journal-title":"Sci. Rep."},{"key":"7018_CR4","doi-asserted-by":"publisher","first-page":"12052","DOI":"10.1038\/s41598-021-91589-2","volume":"11","author":"J Yoon","year":"2021","unstructured":"Yoon, J. et al. Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy. Sci. Rep. 11, 12052 (2021).","journal-title":"Sci. Rep."},{"key":"7018_CR5","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.2147\/OPTH.S285257","volume":"15","author":"S Elfandi","year":"2021","unstructured":"Elfandi, S. et al. Effects of intravitreous aflibercept injection in pachychoroid neovasculopathy: Comparison with typical neovascular age-related macular degeneration. Clin. Ophthalmol. 15, 1539\u20131549 (2021).","journal-title":"Clin. Ophthalmol."},{"key":"7018_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10384-018-0562-0","volume":"62","author":"H Matsumoto","year":"2018","unstructured":"Matsumoto, H. et al. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and type 1 neovascular age-related macular degeneration. Jpn. J. Ophthalmol. 62, 144\u2013150 (2018).","journal-title":"Jpn. J. Ophthalmol."},{"key":"7018_CR7","doi-asserted-by":"publisher","first-page":"e0248760","DOI":"10.1371\/journal.pone.0248760","volume":"16","author":"A Miki","year":"2021","unstructured":"Miki, A. et al. Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. PLoS One 16, e0248760 (2021).","journal-title":"PLoS One"},{"key":"7018_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10384-020-00722-7","volume":"64","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto, H., Mukai, R., Kikuchi, Y., Morimoto, M. & Akiyama, H. One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions. Jpn. J. Ophthalmol. 64, 203\u2013209 (2020).","journal-title":"Jpn. J. Ophthalmol."},{"key":"7018_CR9","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1007\/s00417-023-06030-3","volume":"261","author":"J Takeuchi","year":"2023","unstructured":"Takeuchi, J. et al. Predictive factors for outcomes of half-dose photodynamic therapy combined with aflibercept for pachychoroid neovasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 261, 2235\u20132243 (2023).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"7018_CR10","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1038\/s41433-021-01418-z","volume":"35","author":"T Hikichi","year":"2021","unstructured":"Hikichi, T., Kubo, N. & Yamauchi, M. One-year comparison of anti-vascular endothelial growth factor and half-dose photodynamic therapies for pachychoroid neovasculopathy. Eye (Lond)  35, 3367\u20133375 (2021).","journal-title":"Eye (Lond)"},{"key":"7018_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjophth-2022-001188","volume":"7","author":"R Wang","year":"2022","unstructured":"Wang, R. et al. Quantifying burden of intravitreal injections: Questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII). BMJ Open. Ophthalmol. 7, 1\u20137 (2022).","journal-title":"BMJ Open. Ophthalmol."},{"key":"7018_CR12","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00417-024-06387-z","volume":"262","author":"N Tanaka","year":"2024","unstructured":"Tanaka, N. et al. Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes. Graefes Arch. Clin. Exp. Ophthalmol. 262, 1811\u20131818 (2024).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"7018_CR13","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1007\/s00417-024-06499-6","volume":"262","author":"Y Nomura","year":"2024","unstructured":"Nomura, Y. et al. Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 262, 3191\u20133200 (2024).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"7018_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1089\/jop.2018.0107","volume":"35","author":"HJ Cho","year":"2019","unstructured":"Cho, H. J. et al. Intravitreal Anti-Vascular endothelial growth factor treatment for pachychoroid neovasculopathy. J. Ocul Pharmacol. Ther. 35, 174\u2013181 (2019).","journal-title":"J. Ocul Pharmacol. Ther."},{"key":"7018_CR15","doi-asserted-by":"crossref","unstructured":"Tanaka, K. et al. Two-Thirds dose photodynamic therapy for pachychoroid neovasculopathy. J Clin. Med. 10  (2021).","DOI":"10.3390\/jcm10102168"},{"key":"7018_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10384-020-00740-5","volume":"64","author":"Y Yanagi","year":"2020","unstructured":"Yanagi, Y. Pachychoroid disease: A new perspective on exudative maculopathy. Jpn. J. Ophthalmol. 64, 323\u2013337 (2020).","journal-title":"Jpn J. Ophthalmol."},{"key":"7018_CR17","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00417-020-04661-4","volume":"258","author":"Y Kitajima","year":"2020","unstructured":"Kitajima, Y. et al. One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 258, 1279\u20131285 (2020).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"7018_CR18","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/bjophthalmol-2018-311963","volume":"103","author":"M Miyata","year":"2019","unstructured":"Miyata, M. et al. Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 103, 617\u2013622 (2019).","journal-title":"Br. J. Ophthalmol."},{"key":"7018_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s41433-022-02067-6","volume":"37","author":"K Kawai","year":"2023","unstructured":"Kawai, K. et al. Macular atrophy at 5 years after photodynamic therapy for polypoidal choroidal vasculopathy. Eye (Lond) 37, 1067\u20131072 (2023).","journal-title":"Eye (Lond)"},{"issue":"6.e1\u20132","key":"7018_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ajo.2009.10.011","volume":"149","author":"R Inoue","year":"2010","unstructured":"Inoue, R., Sawa, M., Tsujikawa, M. & Gomi, F. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am. J. Ophthalmol. 149(6.e1\u20132), 441 (2010).","journal-title":"Am. J. Ophthalmol."},{"key":"7018_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ajo.2012.05.001","volume":"154","author":"S Goto","year":"2012","unstructured":"Goto, S., Gomi, F., Ueno, C. & Nishida, K. Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability. Am. J. Ophthalmol. 154, 865\u2013871e1 (2012).","journal-title":"Am. J. Ophthalmol."},{"key":"7018_CR22","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1159\/000519328","volume":"64","author":"W Du","year":"2021","unstructured":"Du, W. et al. Dose-related structural effects of photodynamic therapy on rabbit choroidal structure. Ophthalmic Res. 64, 1037\u20131047 (2021).","journal-title":"Ophthalmic Res."},{"key":"7018_CR23","first-page":"693","volume":"122","author":"A Hayami","year":"2018","unstructured":"Hayami, A., Hara, C., Sawa, M., Sayanagi, K. & Nishida, K. Photodynamic therapy to chronic central serous chorioretinopathy: Outcomes and investigation of poor response. Nippon Ganka Gakkai Zasshi (J. Jpn. Ophthalmol. Soc.) 122, 693\u2013699 (2018).","journal-title":"Nippon Ganka Gakkai Zasshi (J. Jpn. Ophthalmol. Soc.)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07018-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07018-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07018-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:01:47Z","timestamp":1751446907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07018-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7018"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07018-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"12 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23556"}}